Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population

Abstract

Background: Anti-aquaporin-4 antibodies are believed to have a central pathogenetic role in neuromyelitis optica (NMO). B-cell activating factor (BAFF) is one of the crucial factors that determines the fate and survival of B cells and may play a role in induction of antibody-mediated autoimmunity.

Objectives: To evaluate the blood and cerebrospinal fluid (CSF) levels of BAFF in NMO and multiple sclerosis (MS) patients.

Methods: Peripheral blood samples were collected from 21 definite NMO patients, 22 healthy controls and 45 MS patients and CSF from 8 NMO and 11 MS patients. BAFF levels were measured using an ELISA technique.

Results: We found significantly higher levels of BAFF in the CSF of NMO patients compared with that in MS (215.6 ± 41 pg/ml in NMO and 77.4 ± 11 pg/ml in MS, p < 0.001). There were no differences in serum BAFF levels between NMO, MS and healthy donors. MS patients treated with interferon-beta (IFNβ) or glatiramer acetate (GA) had significantly higher serum BAFF levels, as compared with untreated patients (1227 ± 203 pg/ml in untreated MS, 2253 ± 83.4 pg/ml in GA-treated, p < 0.01, and 2106 ± 277.9 pg/ml in interferon-treated, p < 0.05)

Conclusion: The presence of increased BAFF, a soluble factor associated with B-cell activation in the proximity of the disease target organ (CSF) in NMO, and its increase in association with immunomodulating treatments, may help our understanding of the immunopathogenetic mechanisms involved in this disease and contribute to more successful and targeted therapeutic intervention.

Keywords

anti-aquaporin-4 antibodies autoimmunity B-cell activating factor (BAFF)multiple sclerosis (MS)neuromyelitis optica (NMO)

Get full access to this article

View all access options for this article.

References

Antel J. and Bar-Or A. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol 2006; 180: 3-8.

Cayrol R. , Saikali P. and Vincent T. Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica . Ann N Y Acad Sci 2009; 1173: 478-486.

Mackay F. and Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009 ; 9: 491-502.

Groom J. , Kalled SL , Cutler AH , et al. Association of BAFF/ BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest 2002; 109: 59-68.

Cheema GS , Roschke V. , Hilbert DM and Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-1319.

Krumbholz M. , Faber H. , Steinmeyer F. , et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity . Brain 2008; 131: 1455-1463.

Wingerchuk DM , Lennon VA , Pittock SJ , Lucchinetti CF and Weinshenker BG Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.

Okada K. , Matsushita T. , Kira J. and Tsuji S. B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology 2010; 74: 177-178.

MinJH , Kim HJ , KimBJ ,etal.BrainabnormalitiesinSjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica. Mult Scler 2009; 15: 1069-1076.

10.

Pittock SJ , Lennon VA , de Seze J. , et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008; 65: 78-83.

11.

Mehta LR , Samuelsson MK , Kleiner AK , et al. Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome. Mult Scler 2008; 14: 425-427.

12.

Roemer SF , Parisi JE , Lennon VA , et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130: 1194-1205.

13.

Farina C. , Aloisi F. and Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007; 28: 138-145.

14.

Duddy M. and Bar-Or A. B-cells in multiple sclerosis. Int MS J 2006 ; 13: 84-90.

15.

Karussis D. , Teitelbaum D. , Sicsic C. and Brenner T. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J Neuroimmunol 2010; 220: 125-130.

16.

Speciale L. , Saresella M. , Caputo D. , et al. Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b. J Neurovirol 2000; 6(Suppl. 2): S57-S61.